24/7 Market News Snapshot 23 October, 2025 – Entera Bio Ltd. Ordinary Shares (NASDAQ:ENTX)

October 23, 2025

DENVER, Colo., 23 October, 2025 (www.247marketnews.com) – (NASDAQ:ENTX) are discussed in this article.
Entera Bio Ltd. (ENTX) is currently witnessing a notable increase in its stock value, trading at $2.456 during pre-market hours, which marks a robust uptick of 6.78% from the last closing price of $2.30. The trading volume has reached 1.74 million shares, suggesting heightened investor interest and confidence in the company’s prospects. This positive trend may continue, buoyed by substantial buying activity and positive technical indicators, including moving averages and relative strength index (RSI). Should Entera maintain its position above critical support levels, it could offer further opportunities for investors in the foreseeable future.

Simultaneously, Entera Bio is advancing its innovative oral therapy, EB613, which has recently shown promising clinical results at the North American Menopause Society (NAMS) Annual Meeting. The newly revealed data emphasize EB613’s potential to significantly enhance bone mineral density (BMD) in postmenopausal women at high risk for osteoporosis, positioning it uniquely as the first oral anabolic treatment in its category. The findings stem from a comprehensive post-hoc analysis of a Phase 2 trial, demonstrating notable BMD improvements of 3.1% at the lumbar spine, 2.3% at the total hip, and 2.0% at the femoral neck after just six months of treatment with the selected 2.5 mg dose.

Dr. Steven R. Goldstein underscored the critical nature of these results, indicating EB613’s capacity to overcome existing barriers in timely osteoporosis management for early postmenopausal women. He pointed to the remarkable potential of EB613 in enhancing patient outcomes and access to effective therapies. CEO Miranda Toledano expressed optimism about the therapy’s once-daily oral formulation, which is anticipated to improve patient adherence and treatment reach among millions confronting osteoporosis. With plans for a global Phase 3 study slated to commence following regulatory approval, Entera Bio is poised to make significant strides in addressing an urgent unmet need in osteoporosis management.

Related news for (ENTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.